Solabia, a Paris-headquartered biotechnology platform focused on natural active ingredients and diagnostics solutions, has agreed to acquire three complementary businesses as it accelerates its international expansion strategy following investment from Astorg in October 2025.
The transactions include the acquisitions of Mibelle Biochemistry, Seqens’ Botanical Actives and In-Vitro Diagnostics activity, and Xebios Group. Together, the deals broaden Solabia’s product capabilities across natural active ingredients for cosmetics and advanced solutions for diagnostics applications while strengthening the company’s biotechnology platform and global footprint.
Founded in 1972, Solabia develops biotechnology-based ingredients for cosmetics, nutraceutical, pharmaceutical, food, and clinical testing industries. The company uses technologies such as fermentation, enzymatic synthesis, plant extraction, and green chemistry to create high-performance ingredients for global customers.
The first acquisition, Switzerland-based Mibelle Biochemistry, produces science-backed natural active ingredients used in skin care, healthy aging, hair care, and cognitive health products, distributing its solutions in more than 50 countries. The company is known for its plant stem cell technology, which transforms naturally derived compounds into clinically validated cosmetic ingredients.
Solabia is also acquiring Seqens’ Botanical Actives and In-Vitro Diagnostics activity in France, which develops botanical cosmetic ingredients as well as plasma and serum solutions for diagnostic applications. The acquisition strengthens Solabia’s position in botanical actives while securing key raw material supply for its production platform.
The third acquisition, Xebios Group, operates across Germany and the Netherlands and provides microbiological diagnostics solutions for industries including water, food and beverage, and clinical testing. The transaction expands Solabia’s diagnostics footprint in Europe and enhances its innovation capabilities in microbiology.
Combined, the acquisitions expand Solabia’s scale, technical expertise, and geographic reach. The company now operates as a broader biotechnology platform delivering science-driven solutions across natural active ingredients and diagnostic technologies to customers worldwide.
KEY QUOTES:
“We are pleased to welcome Mibelle Biochemistry, Seqens’ Botanical Actives and IVD Activity, and Xebios teams to Solabia. Beyond their strong scientific and technical capabilities, we share a common culture of innovation, quality and long-term client commitment. With the backing of Astorg and TA Associates, we are expanding our ability to serve customers worldwide with a broader and more integrated portfolio of science-driven solutions across beauty, wellbeing and diagnostics. This marks an important step in strengthening Solabia’s position as a scaled, independent biotechnology platform and lays the foundation for continued growth.”
Jean-Baptiste Dellon, Chief Executive Officer of Solabia
“Solabia exemplifies the type of specialised, innovation-driven platform we seek to back. Our deep healthcare and life sciences expertise enables us to assess and execute targeted transactions with conviction, while our entrepreneurial approach and close partnership with management support disciplined, long-term value creation. These acquisitions reflect that focus and mark a significant step in the continued execution of Solabia’s long-term growth strategy.”
Nicolas Marien, Partner, and Paul Arhanchiague, Managing Director, Astorg
